Balance Sheet

Accounts Payables Accumulated Depreciation Accumulated Expenses Assets Cash & Equivalents Common Equity Construction in Progress Current Assets Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Loans - Net Loans - Net Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Accured Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Perspective Therapeutics (CATX) Current Deferred Revenue (2024)

Perspective Therapeutics' Current Deferred Revenue history spans 1 years, with the latest figure at $1.4 million for Q4 2024.

On a quarterly basis, Current Deferred Revenue changed N/A to $1.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was $1.4 million, a N/A change, with the full-year FY2024 number at $1.4 million, changed N/A from a year prior.
Current Deferred Revenue hit $1.4 million in Q4 2024 for Perspective Therapeutics, roughly flat from $1.4 million in the prior quarter.
Over the last five years, Current Deferred Revenue for CATX hit a ceiling of $1.4 million in Q1 2024 and a floor of $1.4 million in Q1 2024.